North America Veterinary Vaccines Market by Type (Livestock Vaccines and Companion Vaccines), by Technology (live attenuated vaccines, inactivated vaccines, recombinant vaccines, toxoid vaccines, subunit vaccines, DNA vaccines and conjugate vaccines) and by region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016-2021)
North America Veterinary Vaccines Market by Type (Livestock Vaccines and Companion Vaccines), by Technology (live attenuated vaccines, inactivated vaccines, recombinant vaccines, toxoid vaccines, subunit vaccines, DNA vaccines and conjugate vaccines) and by region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

**We look forward to being of service to you.**

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk
North America Veterinary Vaccines Market by Type (Livestock Vaccines and Companion Vaccines), by Technology (live attenuated vaccines, inactivated vaccines, recombinant vaccines, toxoid vaccines, subunit vaccines, DNA vaccines and conjugate vaccines) and by region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

The North America animal vaccines market is poised to reach $2171.69 Million by 2020 from $1707.26 Million in 2015, at a CAGR of 4.93% from 2015 to 2020. The major goals of veterinary vaccines are to improve the health companion animals, increase production of livestock in a cost-effective manner, and prevent zoonotic disease transmission from both domestic and wild animals. Veterinary vaccine market has shown significant growth in recent years which can be attributed to increasing husbandry practices and better management of farms. This marks the estimation of further growth in the market due to advancement in biotechnological research.

The North America veterinary vaccines market has undergone considerable progress during the past few years with the growing usage of continuous cell lines as a substrate and embracing of the fermenter technology for antigen production. These vaccines are produced for administration by parenteral or oral routes depending on the vaccine characteristics. But it should be kept in mind that USDA APHIS regulations must be stringently followed for approval and distribution of veterinary biologics across USA which is the major economy in this region.

Growing prevalence of animal diseases, rising incidences of zoonotic diseases in humans; increasing investments by leading players, various government agencies and animal associations; continuous innovations, increasing awareness against the use of antimicrobials is driving the vaccine producers to invest significantly into development of new products. However, rising maintenance costs for the storage of vaccines, increasing adoption of vegetarian diet in major economies owing to increasing risk of obesity and other chronic diseases are key restraints of this market.

The North America veterinary vaccines market has been categorized as livestock and companion vaccines. The livestock vaccines segment has been further segmented into five categories namely, bovine, porcine, ovine, poultry and equine. The companion animal vaccines segment has also been further categorized into feline and canine vaccines. In addition, based on production technologies the market is segmented as live attenuated vaccines, inactivated vaccines, recombinant vaccines, toxoid vaccines, subunit vaccines, DNA vaccines and conjugate vaccines. The canine vaccines segment accounted for a slightly larger share (in terms of revenue) than the feline vaccines segment, due to higher average cost allied with canine vaccination. Similarly, the bovine vaccines sub-segment accounted for the largest share (in terms of revenue), followed by porcine. Furthermore, on the basis of geography, the North America market is analysed under various regions namely, USA and Canada.

Market Data Forecast [MDF] is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients. A few key business areas that we handle with excellence include business process improvement, corporate financing and decision making based on market research, assisting in developing appropriate strategy and providing consultancy based on extensive research.
Table Of Contents for North America Veterinary Vaccines Market by Type (Livestock Vaccines and Companion Vaccines), by Technology (live attenuated vaccines, inactivated vaccines, recombinant vaccines, toxoid vaccines, subunit vaccines, DNA vaccines and conjugate vaccines) and by region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021) [Report Updated: 01-12-2016]

- Introduction
  1.1 Market Definition
  1.2 Study Deliverables
  1.3 Base Currency, Base Year and Forecast Periods
  1.4 General Study Assumptions
- Research Methodology
  2.1 Introduction
  2.2 Analysis Design
  2.3 Research Phases
    2.3.1 Secondary Research
    2.3.2 Primary Research
    2.3.3 Econometric Modelling
    2.3.4 Expert Validation
  2.4 Study Timeline
- Overview
  3.1 Executive Summary
  3.2 Key Inferences
  3.3 New Developments
- Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
  4.1 Market Drivers
  4.2 Market Restraints
  4.3 Key Challenges
  4.4 Current Opportunities in the Market
- Market Segmentation
  5.1 By Type
    5.1.1 Livestock vaccines
      5.1.1.1 Bovine
      5.1.1.2 Porcine
      5.1.1.3 Ovine
      5.1.1.4 Poultry
      5.1.1.5 Equine
    5.1.2 Companion vaccines
      5.1.2.1 Canine
      5.1.2.2 Feline
      5.2 Technology
        5.2.1 Live attenuated vaccines
        5.2.2 Inactivated vaccines
        5.2.3 Recombinant vaccines
        5.2.4 Toxoid vaccines
        5.2.5 Subunit vaccines
        5.2.6 DNA vaccines
        5.2.7 Conjugate vaccines
- Geographical Analysis
  6.1 Introduction
  6.2 United States
  6.3 Canada
- Strategic Analysis
  7.1 PESTLE analysis
    7.1.1 Political
    7.1.2 Economic
    7.1.3 Social
    7.1.4 Technological
    7.1.5 Legal
    7.1.6 Environmental
  7.2 Porter’s Five analysis
    7.2.1 Bargaining Power of Suppliers
    7.2.2 Bargaining Power of Consumers
    7.2.3 Threat of New Entrants
    7.2.4 Threat of Substitute Products and Services
    7.2.5 Competitive Rivalry within the Industry
- Market Leaders’ Analysis
  8.1 Bayer Healthcare AG
    8.1.1 Overview
    8.1.2 Product Analysis
    8.1.3 Financial analysis
    8.1.4 SWOT analysis
    8.1.5 Legal issues
    8.1.6 Recent Developments
  8.2 Bioniche Animal Health Canada
  8.3 Sanofi Animal Health Inc.
  8.4 Biogenesis Bago SA
  8.5 Heska Corporation
  8.6 Indian Immunologicals Ltd.
  8.7 Boehringer Ingelheim GmbH
  8.8 Novartis Animal Health, Inc.
  8.9 Merck & Co. Inc.
  8.10 Protein Sciences
- Competitive Landscape
  9.1 Market share analysis
  9.2 Merger and Acquisition Analysis
  9.3 Agreements, collaborations and Joint Ventures
- New Product Launches
- Expert Opinions
  10.1 Market Outlook
  10.2 Investment Opportunities
- Appendix
  List of Tables
  List of Figures
How to Buy...

North America Veterinary Vaccines Market by Type (Livestock Vaccines and Companion Vaccines), by Technology (live attenuated vaccines, inactivated vaccines, recombinant vaccines, toxoid vaccines, subunit vaccines, DNA vaccines and conjugate vaccines) and by region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021) [Report Updated: 01-12-2016]

Option 1 - Online
Go to our website and pay online with any major debit or credit card:
https://www.bioportfolio.co.uk/product/49377

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: ..................................................................................................................
Job Title: .......................................................................................................................
Your Email: ..................................................................................................................
Your Contact Phone: ..................................................................................................
Company Name: ........................................................................................................
Address: ....................................................................................................................
Post/Zip Code: ...........................................................................................................
Country: ....................................................................................................................
P.O. Number: ............................................................................................................
Any Other Instructions: .............................................................................................

Pricing Options: (please tick one)
☐ $3335 | Single User Price
☐ $3680 | Site License Price
☐ $5520 | Enterprise License Price

Payment Options: (please tick one)
☐ Online Credit Card (we will email you the invoice with a payment link)
☐ Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: ..............................................................................................

Option 3 - Phone Us on +44 (0)7887 945155
We will be delighted to give you our personal attention.